Liver cancer stem cell therapy

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameLiver cancer stem cell therapy
Drug Alias NameHepatocellular carcinoma stem cell therapy (NeoStem Oncology)Tumor stem cell specific dendritic cell therapy (Cellular Biomedicine Group)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesHoag Memorial Hospital Presbyterian
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesHoag Memorial Hospital PresbyterianCellular Biomedicine (Shanghai) Co Ltd
Active IndicationsN/A
Inactive IndicationsCarcinoma, Hepatocellular

Other Information

ATC CodeN/A
Related LinksN/A